NUWENasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Nuwellis, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.56+0.01 (+1.68%)

Close on Oct 19, 2026

Market cap: $101.13K
P/E (TTM): –
Dividend yield: –

Nuwellis, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	8.27	8.74	8.86	8.54	7.92	7.44	5.51	5.00	3.55	1.29	0.06	0.30	0.06	0	–
Cost of Revenue	3.15	3.06	3.88	3.79	3.43	3.38	2.66	3.67	2.76	0.71	–	–	–	–	–
Gross Profit	5.12	5.68	4.98	4.76	4.49	4.06	2.85	1.33	0.79	0.58	–	–	–	–	–
Research & Development	2.71	3.21	5.42	4.34	4.98	3.67	4.67	3.05	1.48	8.11	18	17	14	8.00	11
Selling, General & Admin	14	13	17	18	19	17	16	15	10	8.13	8.35	9.21	9.43	6.87	5.36
Operating Expenses	16	17	23	22	24	21	–	22	18	17	26	26	23	15	17
Total Costs & Expenses	–	–	–	–	–	24	24	22	–	–	–	–	–	–	–
Operating Income	-11	-11	-18	-17	-20	-17	-18	-17	-15	-16	-26	-26	-23	-15	-17
Interest Expense	–	–	–	–	–	–	–	–	–	0.50	0.74	–	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	0.03	0.25
Other Non-Operating Income	0.01	-0.08	0.15	0.08	-0.02	0.00	0	0.01	1.44	-0.18	-0.01	-0.05	-0.10	0.03	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	3.95	0	0	0	0	0	0
Gain (Loss) on Sale of Assets	–	–	–	–	0	-0.04	0	–	–	–	–	–	–	-0.06	–
Pretax Income	-18	-11	-20	-15	-20	-16	-18	-17	-13	-16	-27	-26	-23	-15	-16
Income Tax Expense	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	-0.05	-0.12	-0.25	-1.21	-0.77	-0.12
Net Income	-18	-11	-20	-15	-20	-16	-18	-17	-13	-16	–	–	–	–	–
Preferred Dividends	–	0	0.12	0	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	-18	-11	-23	-15	-20	-18	-23	-17	-25	-18	-27	-26	-22	-14	-16
EPS (Basic)(per share)	-888.65	-12,365.50	-529,288.20	-4,298,647.50	-14,681,772.00	-54,348,178.50	-1,420,591,095.00	-6,439,265,910.00	-80,224,940,565.00	-1,146,916,690,920.00	-1,883,003,938,200.00	-1,938,197,646,000.00	-2,194,912,566,000.00	-2,541,477,708,000.00	-3,825,052,308,000.00
EPS (Diluted)(per share)	-888.65	-12,365.50	-529,288.20	-4,298,647.50	-14,681,772.00	-54,348,178.50	-1,420,591,095.00	-6,439,265,910.00	-80,224,940,565.00	-1,146,916,690,920.00	-1,883,003,938,200.00	-1,938,197,646,000.00	-2,194,912,566,000.00	-2,541,477,708,000.00	-3,825,052,308,000.00
Shares Outstanding (Basic, Weighted)(shares)	0.02	0.00	0.00	0.00	0.00	0	0	0	0	0	0	0	0	0	0
Shares Outstanding (Diluted, Weighted)(shares)	0.02	0.00	0.00	0.00	0.00	0	0	0	0	0	0	0	0	0	0
EBITDA	-11	-11	-17	-17	-19	-17	-18	-17	-14	-15	-26	-26	-23	-15	-17

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 69.7%
Operating margin: -142.9%
Net margin: -125.6%
Return on equity, FY2025: -382.9%

Financial strength

Current ratio: 1.97
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 97.9%

Valuation

P/E ratio: –
Price to sales: 0.01
Price to book: –
Dividend yield: –